Complete assay eliminates the need to split diabetes tests, allowing laboratories to benefit fully from the efficiencies of high-throughput, random access processing
Bayer Diagnostics has launched a new haemoglobin-A1C (HbA1C) assay for use on the Advia 1650 chemistry system, enabling a full panel of diabetes control tests to be consolidated on to this highly productive automated analyser.
Other diabetes control tests available for use on the Advia 1650 include glucose, urinary micro-albumin, urinary protein and serum, and urinary creatinine.
Use of this complete assay panel eliminates the need to split diabetes testing between multiple instruments, allowing laboratories to benefit fully from the efficiencies of high-throughput, random access processing.
This also demonstrates Bayer's commitment to diabetes care.
Using this new assay, the Advia 1650 system measures HbA1C and total haemoglobin concentration in whole blood samples and automatically reports the %HbA1C, freeing laboratory staff from the necessity to calculate this manually.
The assay can be run in random access mode on the Advia 1650 alongside all other analytes on the system, enabling users to deliver an efficient and rapid testing service at the highly productive rate of up to 1650 tests per hour.
To save time in the laboratory, all the reagents are supplied in liquid-stable format ready for use, conveniently packaged in bar-coded wedges.
Reagents remain stable on-board the Advia 1650 for 30 days.
Use of micro-volume technology provides the additional benefit of outstanding reagent efficiency.
Other new assays recently introduced for the Advia 1650 include Digoxin, Gentamicin, Theophylline, Carbamazepine, Phenytoin, Phenobarbital and Valproic acid for therapeutic drug monitoring, plus methods for measuring wide range C-reactive protein, lactate, ammonia and acid phosphatase.
Further new methods for Alpha-1 Antitrypsin, Anti-Streptolysin-O, rheumatoid factor, Lipase, Pancreatic Amylase, prealbumin and urine total protein will be available shortly, as part of Bayer's on-going programme of menu expansion for the instrument.
